Quibron T: Advanced Bronchodilation for Respiratory Relief
Quibron T is a prescription medication formulated to provide comprehensive management of bronchospasm associated with chronic bronchitis, emphysema, and asthma. Combining the bronchodilator theophylline with guaifenesin, an expectorant, it works by relaxing the smooth muscles of the bronchial airways and thinning mucus to facilitate easier expulsion. This dual-action approach not only improves airflow but also enhances the clearance of respiratory secretions, offering patients a more comfortable and effective breathing experience. Clinically trusted and widely prescribed, Quibron T is designed for individuals requiring sustained relief from obstructive airway diseases, supporting both immediate symptom control and long-term respiratory function.
Features
- Contains theophylline anhydrous 300 mg and guaifenesin 100 mg per tablet
- Extended-release formulation for prolonged therapeutic effect
- Designed to reduce bronchospasm and improve mucociliary clearance
- Available in scored tablets for accurate dosing adjustments
- Manufactured under strict pharmaceutical quality standards
Benefits
- Promotes bronchodilation, easing constricted airways and improving oxygen exchange
- Facilitates mucus clearance, reducing cough severity and chest congestion
- Supports sustained symptom control with twice-daily dosing convenience
- Enhances overall respiratory comfort and functional capacity
- May reduce the frequency and severity of acute bronchospastic episodes
- Contributes to improved sleep quality and daily activity levels by alleviating breathing difficulties
Common use
Quibron T is primarily indicated for the symptomatic treatment and prevention of bronchospasm in patients with reversible obstructive airway disease, such as chronic bronchitis and emphysema. It is also used as adjunctive therapy in the management of asthma. Healthcare providers may prescribe it for individuals who experience frequent wheezing, shortness of breath, and chest tightness due to airway constriction and excessive mucus production. Its use is generally reserved for patients who have not achieved sufficient relief from short-acting bronchodilators alone.
Dosage and direction
Dosage must be individualized based on patient factors such as age, weight, smoking status, and concomitant illnesses. The usual starting dose for adults is one tablet (300 mg theophylline/100 mg guaifenesin) every 12 hours. Dosage may be adjusted based on serum theophylline levels and clinical response. Tablets should be swallowed whole and not crushed or chewed. It is recommended to take Quibron T with a full glass of water, and if gastrointestinal upset occurs, it may be taken with food. Regular monitoring of serum theophylline concentrations is advised to maintain levels within the therapeutic range (10–20 mcg/mL).
Precautions
Patients should be advised that Quibron T contains theophylline, which has a narrow therapeutic index and requires careful dosing. Use with caution in individuals with cardiac disorders, hypertension, hyperthyroidism, peptic ulcer disease, or seizure disorders. Elderly patients and those with liver impairment, heart failure, or prolonged fever may exhibit reduced theophylline clearance, increasing the risk of toxicity. Avoid use in individuals with hypersensitivity to any component. Patients should be monitored for signs of theophylline toxicity, such as nausea, vomiting, insomnia, or irregular heartbeat.
Contraindications
Quibron T is contraindicated in patients with a known hypersensitivity to theophylline, guaifenesin, or any component of the formulation. It should not be used in individuals with active peptic ulcer disease or seizure disorders not adequately controlled by anticonvulsant therapy. Concurrent use with other xanthine derivatives is not recommended. The product is also contraindicated in those with uncontrolled cardiac arrhythmias.
Possible side effect
Common side effects may include nausea, vomiting, headache, insomnia, and gastrointestinal discomfort. Less frequently, patients may experience nervousness, restlessness, palpitations, or tachycardia. Serious adverse effects, though rare, can include seizures, cardiac arrhythmias, or severe hypersensitivity reactions. If any severe or persistent side effects occur, medical attention should be sought promptly.
Drug interaction
Quibron T may interact with numerous medications. Theophylline metabolism can be affected by drugs such as cimetidine, erythromycin, ciprofloxacin, and fluvoxamine, which may increase serum levels. Conversely, phenytoin, carbamazepine, and rifampin can decrease theophylline concentrations. Concurrent use with other sympathomimetic agents may potentiate cardiovascular effects. Caution is advised when combining with beta-blockers, as they may antagonize bronchodilator effects. Always inform your healthcare provider of all medications, including over-the-counter drugs and supplements.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to catch up. Consistent dosing is important to maintain therapeutic theophylline levels.
Overdose
Theophylline overdose can be serious and potentially life-threatening. Symptoms may include severe nausea, vomiting, hematemesis, tremors, agitation, hyperthermia, tachycardia, seizures, and cardiac arrest. Management involves immediate discontinuation of the drug, supportive care, and possibly activated charcoal or extracorporeal removal in severe cases. Seek emergency medical attention if overdose is suspected.
Storage
Store at room temperature (20–25°C or 68–77°F), in a tightly closed container, away from moisture, light, and excessive heat. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Dosage and suitability depend on individual patient factors and clinical context.
Reviews
Quibron T has been widely used for decades and is generally regarded as effective for managing bronchospastic conditions when dosed appropriately. Clinical studies and patient reports often highlight its utility in improving respiratory function and reducing symptom frequency. However, individual responses may vary, and careful therapeutic drug monitoring is essential to maximize benefits and minimize risks. Always discuss your treatment experience and any concerns with your prescribing physician.